Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects (Q83888306)
Jump to navigation
Jump to search
scientific article published on 01 June 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects |
scientific article published on 01 June 2006 |
Statements
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects (English)
A R Pettitt
E Matutes